| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | ABT-888 | CTRPv2 | pan-cancer | AAC | -0.0025 | 1 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.0025 | 1 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.0022 | 1 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.0032 | 1 |